Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Peroxisome proliferator-activated receptors (PPARs) have been extensively studied for gene regulation in glucose and lipid metabolism. It has been recently implicated that PPARs regulate cellular proliferation and inflammatory responses; some agonists for PPARs ameliorate experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS) in humans. This article will outline current experimental evidence suggesting potential clinical benefits for patients with MS.
Niino
Masaaki
M
Department of Neurology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. niino@med.hokudai.ac.jp
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry* / Q000627:therapeutic use*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000209:etiology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000276:immunology / Q000502:physiology*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000737:chemistry / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; C039671:ciglitazone; D000077205:Pioglitazone